UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

Clinical cancer research, 2009-04, Vol.15 (8), p.2895-2904

2009

Volltextzugriff (PDF)

Results of the first phase 1 clinical trial of the HER‐2/neu peptide (GP2) vaccine in disease‐free breast cancer patients

Cancer, 2010-01, Vol.116 (2), p.292-301

2010

Volltextzugriff (PDF)

Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/neu Peptide (AE37) Vaccine

Journal of clinical oncology, 2008-07, Vol.26 (20), p.3426-3433

2008

Volltextzugriff (PDF)

Clinical and Immunologic Responses of HLA-A3+ Breast Cancer Patients Vaccinated with the HER2/ neu -Derived Peptide Vaccine, E75, in a Phase I/II Clinical Trial

Journal of the American College of Surgeons, 2010-02, Vol.210 (2), p.140-147

2010

Volltextzugriff (PDF)

Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04

Cancer, 2010-01, Vol.116 (2), p.292-301

2010

Volltextzugriff (PDF)

Longterm Followup Assessment of a HER2/ neu Peptide (E75) Vaccine for Prevention of Recurrence in High-Risk Prostate Cancer Patients

Journal of the American College of Surgeons, 2009-02, Vol.208 (2), p.193-201

2009

Volltextzugriff (PDF)

Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

Cancer, 2008-10, Vol.113 (7), p.1666-1675

2008

Volltextzugriff (PDF)

Concurrent Systemic Chemoimmunotherapy and Sofosbuvir-Based Antiviral Treatment in a Hepatitis C Virus-Infected Patient With Diffuse Large B-Cell Lymphoma

Open forum infectious diseases, 2016-10, Vol.3 (4), p.ofw223-ofw223

2016

Volltextzugriff (PDF)

Circulating regulatory T cells (CD4+ CD25+ FOXP3+ ) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/ neu (AE37) peptide

Vaccine, 2010-11, Vol.28 (47), p.7476-7482

2010

Volltextzugriff (PDF)

AE37: a novel T-cell-eliciting vaccine for breast cancer

Expert opinion on biological therapy, 2011-11, Vol.11 (11), p.1543-1550

2011

Volltextzugriff (PDF)

Central nervous system anaplastic large cell lymphoma in an adult: successful treatment with a combination of radiation and chemotherapy

Military medicine, 2007-06, Vol.172 (6), p.673-675

Carmichael, Mark G

2007

Volltextzugriff (PDF)

Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines

Expert review of vaccines, 2011-02, Vol.10 (2), p.201-210

2011

Volltextzugriff (PDF)

Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

Cancer Immunology, Immunotherapy, 2008-12, Vol.57 (12), p.1817-1825

2008

Volltextzugriff (PDF)

Optimal dose and schedule of an HER‐2/neu (E75) peptide vaccine to prevent breast cancer recurrence

Cancer, 2008-10, Vol.113 (7), p.1666-1675

2008

Volltextzugriff (PDF)

The demonstration of pulmonary neuroendocrine cell hyperplasia with tumorlets in a patient with chronic cough and a history of multiple medical problems

Military medicine, 2005-05, Vol.170 (5), p.439-441

2005

Volltextzugriff (PDF)

14. Impact of Trastuzumab Treatment on HER2/neu Peptide Vaccination-Preliminary Results for a Combination Immunotherapy

The Journal of surgical research, 2008, Vol.144 (2), p.180-181

2008

Volltextzugriff (PDF)

A 59-year-old woman with tuberculous meningitis masked by hepatic encephalopathy

Military medicine, 2003-03, Vol.168 (3), p.266-269

2003

Volltextzugriff (PDF)

Diagnosis of atypical hemolytic uremic syndrome and response to eculizumab therapy

Hawai'i journal of medicine & public health, 2014-09, Vol.73 (9 Suppl 1), p.22-24

2014

Volltextzugriff (PDF)

Abstract LB-414: Comparison of in vitro and in vivo immunologic responses in a prospective, randomized, single-blinded phase II trial evaluating the HER-2/ neu peptide vaccines GP2 and AE37 in breast cancer patients

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.LB-414-LB-414

2011

Volltextzugriff (PDF)

Systemic Mastocytosis: The Difficult Patient with a Rare Disease. Case Presentation and Brief Review

Hawai'i journal of medicine & public health, 2018-02, Vol.77 (2), p.27-29

2018

Volltextzugriff (PDF)

Abstract 2545: Response to a preventive HER2/ neu peptide (E75) vaccine based on HER2/ neu status

Cancer research (Chicago, Ill.), 2008-05, Vol.68 (9_Supplement), p.2545-2545

2008

Volltextzugriff (PDF)

Optimal Dose and Schedule of an HER-2/neu (E75) Peptide Vaccine to Prevent Breast Cancer Recurrence : From US Military Cancer Institute Clinical Trials Group Study 1-01 and 1-02

Cancer, 2008, Vol.113 (7), p.1666-1675

2008

Volltextzugriff (PDF)

Next-Generation Gene Sequencing Differentiates Hypoplastic Myelodysplastic Syndrome from Aplastic Anemia

Hawai'i journal of medicine & public health, 2017-11, Vol.76 (11 Suppl 2), p.10-12

2017

Volltextzugriff (PDF)

Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine : from US Military Cancer Institute Clinical Trials Group Study 1-01 and 1-02

Cancer immunology and immunotherapy, 2008, Vol.57 (12), p.1817-1825

2008

Volltextzugriff (PDF)

Next-Generation Gene Sequencing Differentiates Hypoplastic Myelodysplastic Syndrome from Aplastic Anemia

Hawai'i journal of medicine & public health, 2017-11, Vol.76 (11 Suppl 2), p.10-12

2017

Volltextzugriff (PDF)

1 – 25 von 133

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(122)
Mit Volltextzugriff
(112)

Publikationsform

Sprache

Englisch
(133)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(100)
Humans
(93)
Life Sciences & Biomedicine
(74)
Female
(56)
Male
(47)
Aged
(42)
Alzheimer's Disease
(28)
Middle Aged
(28)
Aged, 80 And Over
(24)
Neurosciences & Neurology
(24)
Magnetic Resonance Imaging
(23)
Clinical Neurology
(22)
Multidisciplinary Sciences
(20)
Science & Technology - Other Topics
(20)
Biological And Medical Sciences
(19)
Medical Sciences
(19)
Neuroimaging
(18)
Adult
(16)
Alzheimer Disease - Diagnostic Imaging
(14)
Alzheimer Disease - Pathology
(14)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Neurology
(10)
Scientific Reports
(8)
Cancer
(6)
Brain
(5)
Nature Communications
(5)
The Journal Of Immunology
(5)
The journal Of Immunology/the journal Of Immunology
(5)
Hawai'i Journal Of Medicine & Public Health
(4)
Blood
(3)
Military Medicine
(3)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

Results of the first phase 1 clinical trial of the HER‐2/neu peptide (GP2) vaccine in disease‐free breast cancer patients

Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/neu Peptide (AE37) Vaccine

Clinical and Immunologic Responses of HLA-A3+ Breast Cancer Patients Vaccinated with the HER2/ neu -Derived Peptide Vaccine, E75, in a Phase I/II Clinical Trial

Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04

Longterm Followup Assessment of a HER2/ neu Peptide (E75) Vaccine for Prevention of Recurrence in High-Risk Prostate Cancer Patients

Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

Concurrent Systemic Chemoimmunotherapy and Sofosbuvir-Based Antiviral Treatment in a Hepatitis C Virus-Infected Patient With Diffuse Large B-Cell Lymphoma

Circulating regulatory T cells (CD4+ CD25+ FOXP3+ ) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/ neu (AE37) peptide

AE37: a novel T-cell-eliciting vaccine for breast cancer

Central nervous system anaplastic large cell lymphoma in an adult: successful treatment with a combination of radiation and chemotherapy

Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines

Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

Optimal dose and schedule of an HER‐2/neu (E75) peptide vaccine to prevent breast cancer recurrence

The demonstration of pulmonary neuroendocrine cell hyperplasia with tumorlets in a patient with chronic cough and a history of multiple medical problems

14. Impact of Trastuzumab Treatment on HER2/neu Peptide Vaccination-Preliminary Results for a Combination Immunotherapy

A 59-year-old woman with tuberculous meningitis masked by hepatic encephalopathy

Diagnosis of atypical hemolytic uremic syndrome and response to eculizumab therapy

Abstract LB-414: Comparison of in vitro and in vivo immunologic responses in a prospective, randomized, single-blinded phase II trial evaluating the HER-2/ neu peptide vaccines GP2 and AE37 in breast cancer patients

Systemic Mastocytosis: The Difficult Patient with a Rare Disease. Case Presentation and Brief Review

Abstract 2545: Response to a preventive HER2/ neu peptide (E75) vaccine based on HER2/ neu status

Optimal Dose and Schedule of an HER-2/neu (E75) Peptide Vaccine to Prevent Breast Cancer Recurrence : From US Military Cancer Institute Clinical Trials Group Study 1-01 and 1-02

Next-Generation Gene Sequencing Differentiates Hypoplastic Myelodysplastic Syndrome from Aplastic Anemia

Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine : from US Military Cancer Institute Clinical Trials Group Study 1-01 and 1-02

Next-Generation Gene Sequencing Differentiates Hypoplastic Myelodysplastic Syndrome from Aplastic Anemia

Suchergebnisse filtern